Targeting nitrated proteins could lead to new cancer drugs
Glioblastoma multiforme is a type of cancer that develops in the brain. Aggressive and difficult to treat, glioblastoma tumors respond to few drugs, and most patients are treated with methods developed about 20 years ago. Kyle Nguyen, a second-year Ph.D. student in Maria Franco’s laboratory at Oregon State University, has been looking for a new way to target these tumors. He will present his work on Friday, 3–3:15 p.m. EDT, at the 2021 ASBMB Annual Meeting.
In broad terms, the Franco lab is interested in the role of oxidative stress in diseases of the nervous system. Oxidative stress is a chemical imbalance inside cells that leads to an accumulation of oxidants that damage healthy cells. It has been linked to aging and various diseases, including cancer. The lab studies the role of oxidants in the development and growth of tumors of the nervous system.
Peroxynitrite is the most powerful oxidant produced in cancer cells and in cells associated with other diseases. When peroxynitrite reacts with proteins it causes oxidative changes that can negatively affect the way the proteins work in the cells. “As far as we know, these are permanent chemical changes,” Nguyen said.
The lab is interested in tyrosine nitration, one of the changes mediated by peroxynitrite. Tyrosine nitration is virtually undetectable in normal tissues, Nguyen explained, so drugs that target nitrated proteins would not affect healthy cells. His project looked at tyrosine nitration of a protein called heat shock protein 90, or Hsp90. Nitrated Hsp90 promotes the survival of tumor cells, and this role is mediated by nitration of tyrosine residues within this protein.
In his work, Nguyen shows that tyrosine nitration supports the survival and migration of glioblastoma cells and thus is important for tumor development, and that nitrated Hsp90 may play more than one role in these tumors. Non-tumor cells do not have nitrated Hsp90 and tumor cells do, so targeting nitrated Hsp90 or other nitrated proteins could selectively kill tumor cells with few side effects.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Early lipid changes drive retinal degeneration in Zellweger spectrum disorder
Lipid profiling in a rare disease mouse model reveals metabolic shifts and inflammation in the retinal pigment epithelium — offering promising biomarker leads to combat blindness.
How sugars shape Marfan syndrome
Research from the University of Georgia shows that Marfan syndrome–associated fibrillin-1 mutations disrupt O glycosylation, revealing unexpected changes that may alter the protein's function in the extracellular matrix.
What’s in a diagnosis?
When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.
Peer through a window to the future of science
Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.
Glow-based assay sheds light on disease-causing mutations
University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.
How signals shape DNA via gene regulation
A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.